Navigation Links
Versartis presents positive preclinical data on 2 product candidates at ENDO 09
Date:6/10/2009

Washington, DC June 10, 2009 Versartis, Inc., an emerging company developing novel biologics with enhanced properties for patients with metabolic diseases, today presented data for its long-acting product candidates, VRS-317 (hGH-rPEG) for treatment of growth hormone deficiency and for VRS-826 (IL-1ra-rPEG) for treatment of type 1 and type 2 diabetes, at the Endocrine Society's Annual Meeting in Washington, DC.

Versartis, through a unique licensing agreement with Amunix, Inc., uses the Amunix proprietary recombinant PEGylation (rPEG) technology to extend the half-life of established biologics. The preclinical Versartis compounds have the potential for significantly less frequent dosing and fewer side effects than those products currently on the market or in development.

"New half-life extension data presented today for the first time confirmed our expectation that dosing can be extended from weekly to monthly for our product candidates," said Jeffrey L. Cleland, Ph.D., Founder and Chief Executive Officer of Versartis. "Our preclinical data presented today show that VRS-317 demonstrated in vivo potency equal to daily hGH, and sustained plasma levels and pharmacodynamic responses in monkeys without toxicity. Potential benefits of VRS-317 include its stability at room temperature in a liquid formulation and the ability to dose monthly with a small gauge needle, thus increasing patient safety and convenience. VRS-317 may become 'best in class' hGH therapy when our preclinical studies are confirmed in human clinical trials."

"Treatment of auto-inflammation in diabetes with IL-1ra has been demonstrated to increase beta-cell responsiveness in human clinical trials," Dr. Cleland continued. "Our new approach with VRS-826 will provide a less frequently administered treatment that should have comparable safety to IL-1ra, which binds both IL-1b and IL-1a. The results from preclinical studies of VRS-317 and VRS-826 are being presented in poster ses
'/>"/>

Contact: Debra Bannister
media@versartis.com
530-676-8001
Versartis, Inc.
Source:Eurekalert

0

GOOD

Page: 1 2

Related biology news :

1. REGiMMUNE presents enhanced efficacy data in preclinical transplantation models
2. Biolex presents Locteron US Phase 2a hepatitis C data at EASL
3. GSA special paper presents new studies of Western US earth motion
4. AIUM Presents 2009 Joseph H. Holmes Pioneer Awards
5. AIUM presents 2009 Memorial Hall of Fame awards
6. AIUM presents 2009 Distinguished Sonographer award
7. AIUM presents 2009 William J. Fry Memorial Lecture award
8. Stevens Center for Science Writings presents: Ravens at the Feast, with Bernd Heinrich, April 1
9. Understanding soil carbon sequestration: New book presents key concepts
10. World Congress on Osteoporosis 2010 presents outstanding scientific program
11. New manual presents robust, state-of-the-art proteomics methods for teaching and research

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...nce that the "synergistic" effect of early-life ex...nd indoor endotoxin causes more harm to developing... Environmental health scientists at the University... that children exposed to both high levels of traf...early life are six times more likely to experience...
(Date:11/23/2009)...lied mathematicians dissected the morphology of th...stic long leaf with a saddle-like arc midsection a...ple cause of the lily,s fan-like shapeelastic rela...growthwas revealed by using an equally simple tech... postdoctoral student at Harvard,s School of Engin...
(Date:11/23/2009)...ociety says that western lowland gorillas living i...e "mother lode" of more than 125,000 gorillas disc...ed by growing humans activity in the region. , T...s adjacent to the southwest border of Lac Tl Commu...igh densities of the great apes still exist in the...
Breaking Biology News(10 mins):Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2The cause behind the characteristic shape of a long leaf revealed 2A year after discovery, Congo's 'mother lode' of gorillas remains vulnerable 2Hard to Treat Diseases Inc 28HTDS 29 Finalizes Agreement with Yunnan Walvax Biotech 48920 1Hard to Treat Diseases Inc 28HTDS 29 Finalizes Agreement with Yunnan Walvax Biotech 48920 2Nicotine Receptors Could Be Lung Cancer Treatment Target 48917 1Nicotine Receptors Could Be Lung Cancer Treatment Target 48917 2Health research agencies form global alliance to curb humanitys most fatal diseases 48914 1Health research agencies form global alliance to curb humanitys most fatal diseases 48914 2
...s Edition:, , Fingerprinting fake coffee , Nan..., Tiny carbon nanotubes show big germ-fighting po...gives nanowires easy access to cells , Memory en...tiny , , , For Wired Readers: , Science Eleme...therine T. (Katie) Hunt on National Public Radio ,...
...arly a century ago that many genes likely influenc... if any, has followed in defining the myriad genes...to this age-old question by pinpointing a genetic ...nsistent genetic link to be reported. , The findi...dition of Nature Genetics, stem from a large-scale...
...Botanists at Oregon State University have discover...o one disease at the same time it produces suscept...s unusual phenomenon has ever been observed in pla...dings of the National Academy of Sciences, may hel...enetic disease resistance can take. Plant diseases...
Other Biology News:American Chemical Society's Weekly Presspac -- Aug. 29, 2007 2American Chemical Society's Weekly Presspac -- Aug. 29, 2007 3American Chemical Society's Weekly Presspac -- Aug. 29, 2007 4American Chemical Society's Weekly Presspac -- Aug. 29, 2007 5American Chemical Society's Weekly Presspac -- Aug. 29, 2007 6American Chemical Society's Weekly Presspac -- Aug. 29, 2007 7American Chemical Society's Weekly Presspac -- Aug. 29, 2007 8Genome study shines light on genetic link to height 2Genome study shines light on genetic link to height 3Same gene protects from 1 disease, opens door to another 2
(Date:11/25/2009)...firmReplikinsLtd.,whichhasanalyzedtheH1N1virus,gen...tbreak,andprogressofthecurrentH1N1pandemic,todayis...atashowsthatthelethalityoftheH1N1("SwineFlu")virus...scurrentoutbreakinthespringof2009torestingnon-epid...ctivitycount,however,remainsincreased. ,, Thene...
(Date:11/25/2009)...linker.comannouncesthatanewmarketresearchreportisa...ketAnalysisandForecaststo2013 ,, http://www.r...Analysis-and-Forecasts-to-2013.html ,, BrazilB...ummary ,, Thereportprovidesdetailedanalysisand...oethanolmarketinparticular.Italsohelpsinanalyzinga...
(Date:11/24/2009)...estment bank KTA Capital,s client Neuren Pharmaceu...ertible note private placement with a U.S. institu...d by KTA Capital as Neuren,s exclusive placement a...ork (PRWEB) November 23, 2009 -- The independent N...A Capital") has announced that its client Neu...
(Date:11/24/2009)...loyment grew by 29,000 jobs in October, and the f...h during the U.S. recession. However, clinics and ...systems are coming closer to having to actually cu...s. , (Vocus) November 24,...in October despite the shedding of jobs in most ot...
Breaking Biology Technology:Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 3Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 6Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 7Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 8Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 9KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4
... , , , , , , Protector RN...or and inhibits a wide known spectrum of,RNases....of enzymes in an assay - even,when high amounts ...f,Protector RNase Inhibitor are needed to protec...r a wide pH range of 5.0 9.0. , Is fully a...
..., , , , , , Protocol Instr..., , , Below, a standard protocol for th...NE 6 is presented that has been specially designed... , , , 1. Prepare cells the day befor...the cells are growing well and are in log phase. O...
..., , , , , , Cells , ...ep an eye on your cells; ensure they are in good c...ol for optimal cell density from the beginning to,..., , Dividing versus Non-dividing Cells ...e for uptake and expression of, foreign DNA...
Other Biology Technology:Protector RNase Inhibitor Enhance the Protection of,RNA against Degradation 2Uses and Applications of FuGENE 6 Transfection Reagent 2Uses and Applications of FuGENE 6 Transfection Reagent 3Uses and Applications of FuGENE 6 Transfection Reagent 4General Considerations for Successful Transfection Experiments 2
Mun I (Mfe I) from Takara Mirus Bio
Tissue Trans-glutaminase-directed IgA EIA Kit from Alpco Diagnostics
...CR (MSP) is a new technology for sensitive detecti...ounts of DNA (5). This process employs an initial ...PCR amplification with specific primers designed t...e CpGenome™ DNA Modification Kit (S7820) con...
iEMS Incubator/Shaker HT from Thermo Scientific
Biology Products: